| Identification | Back Directory | [Name]
2-Thiopheneacetamide, 4-bromo-N-[4-[[6-methyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]- | [CAS]
2716890-91-2 | [Synonyms]
2-Thiopheneacetamide, 4-bromo-N-[4-[[6-methyl-2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]- | [Molecular Formula]
C21H22BrN5OS | [MOL File]
2716890-91-2.mol | [Molecular Weight]
472.4 |
| Chemical Properties | Back Directory | [density ]
1.513±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (211.69 mM; Need ultrasonic) | [form ]
Solid | [pka]
13.34±0.70(Predicted) | [color ]
Off-white to gray |
| Hazard Information | Back Directory | [Biological Activity]
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 μM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties[1]. | [storage]
Store at -20°C | [References]
[1]. Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961. |
|
|